Anglo-Swedish pharma company AstraZeneca (LON: AZN) will join forces with US biotech firm Moderna Therapeutics to co-develop and co-commercialize immuno-oncology mRNA therapeutics, it has been announced.
The collaboration will combine AstraZeneca’s protein engineering and biology expertise with Moderna’s mRNA platform.
The partnership is in addition to an agreement announced in 2013 to develop mRNA Therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze